Converge Bio

About Converge Bio

Converge Bio accelerates drug development through GenAI-powered innovations in discovery, molecule design, and manufacturing to create future therapies. The company emphasizes rapid, AI-assisted antibody discovery, de novo design, and process optimization to streamline lead selection and reduce wet-lab screening. Its platform combines generative modeling, binding and developability prediction, and cell- and patient-level simulations to anticipate outcomes across therapeutic modalities. Headquartered with a focus on biotechnology innovation, Converge Bio positions itself at the intersection of computational biology and biopharmaceutical development.